Cohance Lifesciences Limited on Wednesday reported a consolidated net loss of Rs 24.1 crore for the first quarter of FY27, compared to a net profit of Rs 48.9 crore in the corresponding quarter of the previous financial year. Its operating performance also weakened sharply, with EBITDA declining 99 per cent to Rs 1.2 crore from Rs 112 crore in the year-ago quarter. Despite the weak quarterly performance, Cohance Lifesciences' shares ended the trading session marginally higher. Over the past five days, the company's shares remained largely unchanged, gaining just 0.34 per cent. Hyderabad-based Cohance Lifesciences is a technology-driven global Contract Development and Manufacturing Organization (CDMO) and active pharmaceutical ingredient (API) platform.